BNP Paribas Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

BNP Paribas Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.1M	Buy	976,103 +584,516	+149%	+$19.5M	0.03%	456
2026 Q1	$11.8M	Buy	391,587 +346,953	+777%	+$11.2M	0.01%	659
2025 Q4	$1.4M	Sell	44,634 -5,277	-11%	-$130K	﹤0.01%	1120
2025 Q3	$1.01M	Sell	49,911 -10,015	-17%	-$176K	﹤0.01%	686
2025 Q2	$1M	Buy	59,926 +34,454	+135%	+$556K	﹤0.01%	755
2025 Q1	$391K	Buy	+25,472	New	+$455K	﹤0.01%	821
2021 Q2	–	Sell	-13,572	Closed	-$157K	–	933
2021 Q1	$157K	Sell	13,572 -3,991	-23%	-$45.8K	﹤0.01%	836
2020 Q4	$169K	Sell	17,563 -11,694	-40%	-$112K	﹤0.01%	835
2020 Q3	$264K	Buy	29,257 +17,132	+141%	+$181K	﹤0.01%	790
2020 Q2	$150K	Buy	+12,125	New	+$137K	﹤0.01%	798
2019 Q2	–	Sell	-28,168	Closed	-$442K	–	952
2019 Q1	$442K	Sell	28,168 -5,404	-16%	-$95.3K	﹤0.01%	811
2018 Q4	$527K	Sell	33,572 -16,220	-33%	-$333K	﹤0.01%	795
2018 Q3	$1.06M	Hold	49,792	–	–	0.01%	698
2018 Q2	$1.22M	Sell	49,792 -75,520	-60%	-$1.54M	0.01%	705
2018 Q1	$2.14M	Buy	+125,312	New	+$2.45M	0.02%	626
2016 Q4	–	Sell	-25,521	Closed	-$1.17M	–	1065
2016 Q3	$1.17M	Sell	25,521 -541	-2%	-$28.2K	0.01%	810
2016 Q2	$1.31M	Hold	26,062	–	–	0.01%	767
2016 Q1	$1.4M	Sell	26,062 -62,337	-71%	-$3.66M	0.01%	752
2015 Q4	$5.8M	Sell	88,399 -1,842	-2%	-$114K	0.05%	423
2015 Q3	$5.09M	Buy	90,241 +13,010	+17%	+$844K	0.04%	463
2015 Q2	$4.56M	Buy	77,231 +10,672	+16%	+$658K	0.04%	519
2015 Q1	$4.15M	Buy	66,559 +22,445	+51%	+$1.3M	0.03%	545
2014 Q4	$2.54M	Sell	44,114 -1,813	-4%	-$101K	0.02%	569
2014 Q3	$2.47M	Sell	45,927 -4,984	-10%	-$264K	0.02%	582
2014 Q2	$2.67M	Sell	50,911 -83,972	-62%	-$4.29M	0.02%	588
2014 Q1	$7.13M	Buy	134,883 +99,997	+287%	+$4.62M	0.05%	353
2013 Q4	$1.4M	Sell	34,886 -1,169	-3%	-$46K	0.01%	689
2013 Q3	$1.36M	Sell	36,055 -32,366	-47%	-$1.26M	0.01%	666
2013 Q2	$2.68M	Buy	+68,421	New	+$2.66M	0.02%	557

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

BNP Paribas Asset Management's TEVA Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 149% in Q2 2026, buying an estimated $19.5M and bringing the position to 976,103 shares worth $33.1M. The position accounts for 0.03% of the portfolio, ranked #456.

BNP Paribas Asset Management first reported a position in TEVA in Q2 2013 and has held it in 29 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

BNP Paribas Asset Management held 976,103 shares of Teva Pharmaceuticals worth $33.1M as of Q2 2026.
BNP Paribas Asset Management bought 584,516 Teva Pharmaceuticals shares in Q2 2026, an estimated $19.5M.
Teva Pharmaceuticals made up 0.03% of BNP Paribas Asset Management's portfolio in Q2 2026, its #456 holding.
BNP Paribas Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 29 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.